The International Journal of Neuropsychopharmacology
September 1, 2026
K Kusudo, K Yonezawa, Sota Tomiyama et al.
Abstract Background Psilocybin, a prodrug metabolized to psilocin, a serotonin 2A receptor agonist, has reemerged as a promising therapeutic option for treatment-resistant depression (TRD). Clinical trials conducted mainly in North America and Europe have demonstrated that psilocybin administered with psychological support can produce rapid and sustained antidepressant effects with favorable...
The International Journal of Neuropsychopharmacology
September 1, 2026
K Yonezawa, K Kusudo, Sota Tomiyama et al.
Abstract Background Despite recent advances in the treatment of major depression, approximately 30% of patients show insufficient improvement with conventional antidepressants, a condition commonly referred to as treatment-resistant depression (TRD). Psilocybin is a classic psychedelic compound that has received renewed attention as a promising therapeutic candidate for TRD. Clinical trials...
Zenodo (CERN European Organization for Nuclear Research)
August 31, 2026
preprint
Evidence for psilocybin use in chronic depression is limited, primarily focusing on treatment-resistant cases. While promising results have been noted in studies, more targeted and extensive research is needed.
European Journal of Drug Metabolism and Pharmacokinetics
August 28, 2026
Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
Nature Medicine
August 6, 2026
James Rucker, Tim Mantingh, Jess Kerr-Gaffney et al.
1 citation
Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health...
British Journal of Mental Health Nursing
August 2, 2026
Rachel Sinclair
Depression remains a significant public health concern worldwide and many individuals do not achieve adequate symptom relief from conventional treatments such as antidepressants and psychological therapies. Interest has therefore increased in alternative interventions, including psilocybin microdosing. This article aimed to critically review the current evidence regarding the use of psilocybin...
EBioMedicine
August 1, 2026
The use of psilocybin for treatment-resistant depression (TRD) is moving towards clinical use, and two unresolved questions will shape what comes next: how large and durable the benefit is, and what produces it? The strongest peer-reviewed efficacy signal is a phase 2b trial, in which one dose of synthetic psilocybin with psychological support approximately doubled the depression-score...
Journal of Affective Disorders
August 1, 2026
Taro Kishi, Kenji Sakuma, Masakazu Hatano et al.
This systematic review and meta-analysis of six randomized controlled trials aimed to investigate the temporal changes in the efficacy and safety of psilocybin treatment for major depressive disorder (MDD). Separate meta-analyses were conducted for standard-dose psilocybin (25 mg/session, or 20-30 mg/70 kg/session) and low-dose psilocybin (10 mg/session or 15.05 mg/70 kg/session) subgroups....
Journal of Affective Disorders
August 1, 2026
Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al.
2 citations
The contribution of patient support to psilocybin's antidepressant effects remains uncertain. Relationships between therapeutic alliance (Scale to Assess Therapeutic Relationship-Patient version; STAR-P), psychedelic experience (Five-Dimensional Altered States of Consciousness Questionnaire and Emotional Breakthrough Inventory; 5D-ASC and EBI) and clinical outcomes (Montgomery-Åsberg Depression...
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
July 28, 2026
Danial O. Beniameen, Armya O. Beniameen
Background: Major depressive disorder (MDD) affects over 280 million people globally and remains a leading cause of disability. Psilocybin has emerged as a promising treatment, with evidence suggesting modulation of neural oscillatory activity relevant to mood regulation. Electroencephalography (EEG) and magnetoencephalography (MEG) offer non-invasive methods for evaluating these...